Cas:1204051-93-3 B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid manufacturer & supplier

Chemical Name:B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid

CAS.NO:1204051-93-3

Synonyms:B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid

Molecular Formula:C₂₁H₂₅BF₂O₂

Molecular Weight:358.2298064

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid Use and application,B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid technical grade,usp/ep/jp grade.

Related News: Taiwan complained on Sunday that it was being punished because the World Health Organization considers it part of China, which has been subject to travel bans as the coronavirus spreads. B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid manufacturer Taiwan complained on Sunday that it was being punished because the World Health Organization considers it part of China, which has been subject to travel bans as the coronavirus spreads. B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid supplier With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs. B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid vendor The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. B-[3,5-Difluoro-4′-(trans-4-propylcyclohexyl)[1,1′-biphenyl]-4-yl]boronic acid factory The survival benefit is “unprecedented” for an aging myeloma population, almost all of whom were 65 years of age or older, said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.